Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Dcc-3014
2. 1628606-05-2
3. Vimseltinib [inn]
4. Vimseltinib [usan]
5. Px9ftm69bf
6. Dcc3014
7. 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1h-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3h)-one
8. 3-methyl-5-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-(propan-2-ylamino)pyrimidin-4-one
9. Dp-6865
10. 3-methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1h-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-4(3h)-pyrimidinone
11. 4(3h)-pyrimidinone, 3-methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1h-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-
12. Unii-px9ftm69bf
13. Vimseltinib [who-dd]
14. Schembl16047448
15. Gtpl11190
16. Ex-a4700
17. Nsc828316
18. Who 11443
19. Nsc-828316
20. Example 10 [wo2014145025a2]
21. Hy-136256
22. Cs-0121044
23. 3-methyl-5-(6-methyl-5-{[2-(1-methyl-1h-pyrazol-4-yl)pyridin-4-yl]oxy}pyridin-2-yl)-2-[(propan-2-yl)amino]pyrimidin-4(3h)-one
24. Z6v
| Molecular Weight | 431.5 g/mol |
|---|---|
| Molecular Formula | C23H25N7O2 |
| XLogP3 | 1.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 6 |
| Exact Mass | 431.20697307 g/mol |
| Monoisotopic Mass | 431.20697307 g/mol |
| Topological Polar Surface Area | 97.5 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 740 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
DCC-3014 (vimseltinib) is a CSF1R inhibitor small molecule drug candidate, which is being evaluated for the treatment of patients with tenosynovial giant cell tumor.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Brand Name: DCC-3014
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2024
Lead Product(s) : Vimseltinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Accepts Deciphera’s NDA for Vimseltinib to Treat Tenosynovial Giant Cell Tumor
Details : DCC-3014 (vimseltinib) is a CSF1R inhibitor small molecule drug candidate, which is being evaluated for the treatment of patients with tenosynovial giant cell tumor.
Brand Name : DCC-3014
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 15, 2024
Details:
DCC-3014 (vimseltinib) is a CSF1R inhibitor small molecule drug candidate, which is being evaluated for the treatment of patients with tenosynovial giant cell tumor.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Brand Name: DCC-3014
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2024
Lead Product(s) : Vimseltinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EMA Accepts Deciphera’s MAA for Vimseltinib for Tenosynovial Giant Cell Tumor
Details : DCC-3014 (vimseltinib) is a CSF1R inhibitor small molecule drug candidate, which is being evaluated for the treatment of patients with tenosynovial giant cell tumor.
Brand Name : DCC-3014
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 18, 2024
Details:
DCC-3014 (vimseltinib) is an oral, switch control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R by exploiting unique features of the switch control region that regulates kinase conformational activation.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Brand Name: DCC-3014
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Lead Product(s) : Vimseltinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DCC-3014 (vimseltinib) is an oral, switch control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R by exploiting unique features of the switch control region that regulates kinase conformational activation.
Brand Name : DCC-3014
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 30, 2023
Details:
DCC-3014 (vimseltinib) is an oral, switch control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R by exploiting unique features of the switch control region that regulates kinase conformational activation.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Brand Name: DCC-3014
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Lead Product(s) : Vimseltinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DCC-3014 (vimseltinib) is an oral, switch control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R by exploiting unique features of the switch control region that regulates kinase conformational activation.
Brand Name : DCC-3014
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 01, 2023
Details:
Deciphera intends to use the proceeds to fund its planned Phase 3 INSIGHT study of QINLOCK versus sunitinib, to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Brand Name: DCC-3014
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: J.P. Morgan
Deal Size: $143.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 24, 2023
Lead Product(s) : Vimseltinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $143.7 million
Deal Type : Public Offering
Details : Deciphera intends to use the proceeds to fund its planned Phase 3 INSIGHT study of QINLOCK versus sunitinib, to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tum...
Brand Name : DCC-3014
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 24, 2023
Details:
Deciphera intends to use the net proceeds from the offering to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients currently underway.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Brand Name: DCC-3014
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: J.P. Morgan
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 19, 2023
Lead Product(s) : Vimseltinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $125.0 million
Deal Type : Public Offering
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Details : Deciphera intends to use the net proceeds from the offering to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients currently underway.
Brand Name : DCC-3014
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 19, 2023
Details:
Deciphera intends to use the net proceeds from the offering to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients currently underway.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Brand Name: DCC-3014
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: J.P. Morgan
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 18, 2023
Lead Product(s) : Vimseltinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $125.0 million
Deal Type : Public Offering
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock
Details : Deciphera intends to use the net proceeds from the offering to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients currently underway.
Brand Name : DCC-3014
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 18, 2023
Details:
Updated Results for DCC-3014 (vimseltinib) Showed Objective Response Rate of 69% in Phase 1, 53% in Phase 2 Cohort A, and 46% in Phase 2 Cohort B; Demonstrated a Clinical Benefit Rate of 100% Across All Phase 1/2 Patients.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Brand Name: DCC-3014
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2022
Lead Product(s) : Vimseltinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Updated Results for DCC-3014 (vimseltinib) Showed Objective Response Rate of 69% in Phase 1, 53% in Phase 2 Cohort A, and 46% in Phase 2 Cohort B; Demonstrated a Clinical Benefit Rate of 100% Across All Phase 1/2 Patients.
Brand Name : DCC-3014
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 11, 2022
Details:
DCC-3014 (vimseltinib) is an investigational, orally administered, potent and highly selective switch-control kinase inhibitor of CSF1R. Vimseltinib was discovered using our proprietary drug discovery platform and was designed to selectively bind to the CSF1R switch pocket.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Brand Name: DCC-3014
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
Lead Product(s) : Vimseltinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DCC-3014 (vimseltinib) is an investigational, orally administered, potent and highly selective switch-control kinase inhibitor of CSF1R. Vimseltinib was discovered using our proprietary drug discovery platform and was designed to selectively bind to the ...
Brand Name : DCC-3014
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 01, 2022
Details:
Deciphera intends to use the net proceeds from the offering to continue to fund the development of vimseltinib including in its pivotal Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients currently underway, additional clinical trials.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Brand Name: DCC-3014
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: J.P. Morgan
Deal Size: $172.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 29, 2022
Lead Product(s) : Vimseltinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $172.5 million
Deal Type : Public Offering
Details : Deciphera intends to use the net proceeds from the offering to continue to fund the development of vimseltinib including in its pivotal Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients currently underway, additional clinical ...
Brand Name : DCC-3014
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 29, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Vimseltinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vimseltinib, including repackagers and relabelers. The FDA regulates Vimseltinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vimseltinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Vimseltinib supplier is an individual or a company that provides Vimseltinib active pharmaceutical ingredient (API) or Vimseltinib finished formulations upon request. The Vimseltinib suppliers may include Vimseltinib API manufacturers, exporters, distributors and traders.
Vimseltinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Vimseltinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Vimseltinib GMP manufacturer or Vimseltinib GMP API supplier for your needs.
A Vimseltinib CoA (Certificate of Analysis) is a formal document that attests to Vimseltinib's compliance with Vimseltinib specifications and serves as a tool for batch-level quality control.
Vimseltinib CoA mostly includes findings from lab analyses of a specific batch. For each Vimseltinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Vimseltinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Vimseltinib EP), Vimseltinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vimseltinib USP).
LOOKING FOR A SUPPLIER?
